Clinical bottom line
Early administration of intravenous ceftolozane-tazobactam in the emergency department (ED) may offer a promising therapeutic option for patients with suspected or confirmed multidrug-resistant (MDR) Pseudomonas aeruginosa infections, particularly in high-risk populations such as immunocompromised patients. Emerging evidence suggests that ceftolozane-tazobactam demonstrates favorable clinical outcomes and microbiological efficacy compared to older agents, with a potentially improved safety profile. However, data remain limited primarily to observational studies and select patient cohorts, warranting cautious interpretation and further validation in the ED setting.
What the evidence shows
Ceftolozane-tazobactam is a novel cephalosporin-beta-lactamase inhibitor combination specifically designed to target MDR P. aeruginosa, including strains resistant to carbapenems and other beta-lactams. Clinical experience with this agent has expanded over the last decade, including in populations often encountered in emergency care.
Several observational studies and systematic reviews have reported on the effectiveness of ceftolozane-tazobactam in treating MDR P. aeruginosa infections. King et al. (2018) conducted a multicenter study focusing on bloodstream infections caused by MDR P. aeruginosa, demonstrating that early use of ceftolozane-tazobactam was associated with improved clinical outcomes and reduced mortality compared to historical controls treated with alternative regimens. Similarly, Hakki et al. (2018) reported favorable outcomes in hematologic malignancy and hematopoietic-cell transplant patients, a group at high risk for resistant infections, with ceftolozane-tazobactam therapy showing good tolerability and microbiological clearance.
A systematic review and meta-analysis comparing ceftolozane-tazobactam to ceftazidime-avibactam for difficult-to-treat resistant P. aeruginosa infections found comparable efficacy but suggested a trend toward fewer adverse events with ceftolozane-tazobactam (2026). This supports its potential role as a first-line agent in certain MDR scenarios.
In pediatric populations, Molloy et al. (2020) described successful use of ceftolozane-tazobactam for MDR P. aeruginosa infections, highlighting its expanding applicability beyond adults. Additionally, Gelfand et al. (2015) reported on respiratory infections due to MDR P. aeruginosa, where ceftolozane-tazobactam demonstrated promising microbiological and clinical response rates.
Faculty Opinions’ post-publication peer review by Lortholary et al. (2018) emphasized the clinical effectiveness of ceftolozane-tazobactam and noted the ongoing concern of emerging resistance, underscoring the need for stewardship and susceptibility-guided therapy.
Caveats and uncertainty
Despite encouraging data, the evidence base for early ED use of ceftolozane-tazobactam remains limited by several factors:
- Most studies are observational, retrospective, or from specialized centers, limiting generalizability to the broader ED population.
- Randomized controlled trials specifically evaluating early initiation in the ED setting are lacking.
- Resistance to ceftolozane-tazobactam, although currently low, has been reported and may increase with widespread use (Lortholary et al., 2018).
- Optimal dosing strategies and duration of therapy in the acute care setting remain to be fully defined.
- Cost and availability may limit immediate adoption in some institutions.
- The role of ceftolozane-tazobactam relative to other novel agents such as ceftazidime-avibactam requires further head-to-head comparison in emergency scenarios (2026 systematic review).
How this may change practice
Emergency clinicians should consider ceftolozane-tazobactam as a potential early treatment option for patients presenting with suspected or confirmed MDR P. aeruginosa infections, especially in those with risk factors such as immunocompromise, prior antibiotic exposure, or healthcare-associated infections. Early initiation in the ED could improve clinical outcomes by providing targeted therapy before definitive culture results.
Integration of rapid diagnostic tools and antimicrobial stewardship protocols will be critical to optimize use and minimize resistance development. Clinicians should remain vigilant for emerging resistance patterns and tailor therapy accordingly.
Further prospective studies and ED-specific guidelines are needed to clarify patient selection, timing, and dosing. Meanwhile, multidisciplinary collaboration with infectious disease specialists is advisable when considering ceftolozane-tazobactam in the emergency setting.